JP2017502920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502920A5 JP2017502920A5 JP2016524999A JP2016524999A JP2017502920A5 JP 2017502920 A5 JP2017502920 A5 JP 2017502920A5 JP 2016524999 A JP2016524999 A JP 2016524999A JP 2016524999 A JP2016524999 A JP 2016524999A JP 2017502920 A5 JP2017502920 A5 JP 2017502920A5
- Authority
- JP
- Japan
- Prior art keywords
- binding fragment
- pharmaceutical composition
- antigen
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893814P | 2013-10-21 | 2013-10-21 | |
| US61/893,814 | 2013-10-21 | ||
| US201461979384P | 2014-04-14 | 2014-04-14 | |
| US61/979,384 | 2014-04-14 | ||
| US201462012805P | 2014-06-16 | 2014-06-16 | |
| US62/012,805 | 2014-06-16 | ||
| PCT/US2014/061592 WO2015061330A1 (en) | 2013-10-21 | 2014-10-21 | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018241924A Division JP6875363B2 (ja) | 2013-10-21 | 2018-12-26 | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502920A JP2017502920A (ja) | 2017-01-26 |
| JP2017502920A5 true JP2017502920A5 (enExample) | 2017-11-24 |
| JP6461944B2 JP6461944B2 (ja) | 2019-01-30 |
Family
ID=52826380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524999A Active JP6461944B2 (ja) | 2013-10-21 | 2014-10-21 | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 |
| JP2018241924A Active JP6875363B2 (ja) | 2013-10-21 | 2018-12-26 | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018241924A Active JP6875363B2 (ja) | 2013-10-21 | 2018-12-26 | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9598495B2 (enExample) |
| EP (3) | EP3060252B1 (enExample) |
| JP (2) | JP6461944B2 (enExample) |
| KR (4) | KR102308493B1 (enExample) |
| CN (2) | CN116966293A (enExample) |
| AU (3) | AU2014340210B2 (enExample) |
| BR (1) | BR112016009047B1 (enExample) |
| CA (2) | CA2927841C (enExample) |
| DK (1) | DK3060252T3 (enExample) |
| EA (1) | EA033072B1 (enExample) |
| ES (2) | ES2773961T3 (enExample) |
| IL (3) | IL275720B (enExample) |
| MX (2) | MX374708B (enExample) |
| NZ (1) | NZ630892A (enExample) |
| PL (1) | PL3060252T3 (enExample) |
| PT (1) | PT3060252T (enExample) |
| SG (2) | SG11201603167YA (enExample) |
| WO (1) | WO2015061330A1 (enExample) |
| ZA (1) | ZA201602686B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2427212T3 (pl) | 2009-05-08 | 2018-02-28 | Vaccinex, Inc. | Przeciwciała anty cd-100 i sposoby ich zastosowania |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| WO2014116982A2 (en) * | 2013-01-25 | 2014-07-31 | Brandeis University | Methods of modulating gabaergic inhibitory synapse formation and function |
| SG10201902380SA (en) | 2013-06-25 | 2019-04-29 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP4059516A1 (en) | 2016-04-22 | 2022-09-21 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| JP7084689B2 (ja) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | 脳組織の異常を伴う非ヒト動物の作製方法およびその利用 |
| WO2018156509A1 (en) * | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| US11572408B2 (en) | 2017-03-20 | 2023-02-07 | Vaccinex, Inc. | Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent |
| IL270244B2 (en) | 2017-05-05 | 2025-01-01 | Vaccinex Inc | Antibody against human semaphorin 4D |
| CN109410218B (zh) * | 2018-10-08 | 2020-08-11 | 百度在线网络技术（北京）有限公司 | 用于生成车辆损伤信息的方法和装置 |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| WO2022137964A1 (ja) * | 2020-12-23 | 2022-06-30 | 国立大学法人大阪大学 | 軟骨・骨・関節疾患の予防または治療用医薬組成物および軟骨・骨・関節疾患の予防または治療用薬剤のスクリーニング方法 |
| JP2024535403A (ja) * | 2021-09-27 | 2024-09-30 | バクシネックス インコーポレーティッド | 神経変性障害を処置するための抗セマフォリン４ｄ結合分子の使用に関する予測アウトカムプロファイリング |
| US20230101618A1 (en) * | 2021-09-27 | 2023-03-30 | Vaccinex, Inc. | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| WO2023154906A1 (en) | 2022-02-13 | 2023-08-17 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| CN121219322A (zh) * | 2023-04-03 | 2025-12-26 | 赛尔生物股份有限公司 | 包含重组抗信号素4d阻断抗体作为有效成分的用于预防或治疗干燥综合征的药物组合物 |
| CN117924494B (zh) * | 2024-01-23 | 2025-02-25 | 首都医科大学附属北京积水潭医院 | 特异性结合sema4d的抗原结合蛋白及其应用 |
| WO2026030311A1 (en) * | 2024-07-29 | 2026-02-05 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules to treat cognitive impairment |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| IL132240A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Anti-vegf antibodies |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| ATE407206T1 (de) | 1998-11-10 | 2008-09-15 | Univ Rochester | Methoden zu herstellung von genbanken |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| AU2913801A (en) | 1999-12-23 | 2001-07-03 | Cornell Research Foundation Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| NZ621449A (en) | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| WO2005058965A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| PT1773885E (pt) | 2004-08-05 | 2010-07-21 | Genentech Inc | Antagonistas anti-cmet humanizados |
| US20060147449A1 (en) * | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| WO2006110594A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Sema4d in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| DE602008004296D1 (de) | 2007-02-14 | 2011-02-17 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| PE20091378A1 (es) | 2008-01-10 | 2009-10-14 | Genentech Inc | Polipeptidos agonistas plexind1 |
| PL2427212T3 (pl) * | 2009-05-08 | 2018-02-28 | Vaccinex, Inc. | Przeciwciała anty cd-100 i sposoby ich zastosowania |
| JP5797190B2 (ja) | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス， インコーポレイテッド | ワクチン免疫療法 |
| AU2011267869A1 (en) | 2010-06-14 | 2013-01-10 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| PT2711023T (pt) | 2011-05-13 | 2017-10-02 | Univ Nat Corp Tokyo Medical & Dental | Promotor da osteogénese |
| EA029023B1 (ru) * | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| SG10201902380SA (en) | 2013-06-25 | 2019-04-29 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP4059516A1 (en) | 2016-04-22 | 2022-09-21 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| WO2018156509A1 (en) | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
-
2014
- 2014-09-11 NZ NZ630892A patent/NZ630892A/en unknown
- 2014-10-21 EP EP14855074.2A patent/EP3060252B1/en active Active
- 2014-10-21 CN CN202310282388.8A patent/CN116966293A/zh active Pending
- 2014-10-21 JP JP2016524999A patent/JP6461944B2/ja active Active
- 2014-10-21 PT PT148550742T patent/PT3060252T/pt unknown
- 2014-10-21 US US14/519,965 patent/US9598495B2/en active Active
- 2014-10-21 EA EA201690813A patent/EA033072B1/ru unknown
- 2014-10-21 SG SG11201603167YA patent/SG11201603167YA/en unknown
- 2014-10-21 CA CA2927841A patent/CA2927841C/en active Active
- 2014-10-21 CA CA3193983A patent/CA3193983A1/en active Pending
- 2014-10-21 KR KR1020167013445A patent/KR102308493B1/ko active Active
- 2014-10-21 BR BR112016009047-0A patent/BR112016009047B1/pt active IP Right Grant
- 2014-10-21 KR KR1020217030075A patent/KR20210118246A/ko not_active Ceased
- 2014-10-21 WO PCT/US2014/061592 patent/WO2015061330A1/en not_active Ceased
- 2014-10-21 DK DK14855074.2T patent/DK3060252T3/da active
- 2014-10-21 ES ES14855074T patent/ES2773961T3/es active Active
- 2014-10-21 PL PL14855074T patent/PL3060252T3/pl unknown
- 2014-10-21 ES ES19208515T patent/ES3063301T3/es active Active
- 2014-10-21 CN CN201480070232.2A patent/CN106029093B/zh active Active
- 2014-10-21 EP EP19208515.7A patent/EP3639853B1/en active Active
- 2014-10-21 KR KR1020237038769A patent/KR20230159633A/ko not_active Ceased
- 2014-10-21 MX MX2016005050A patent/MX374708B/es active IP Right Grant
- 2014-10-21 SG SG10201707786QA patent/SG10201707786QA/en unknown
- 2014-10-21 EP EP26151245.3A patent/EP4717270A2/en active Pending
- 2014-10-21 IL IL275720A patent/IL275720B/en unknown
- 2014-10-21 AU AU2014340210A patent/AU2014340210B2/en active Active
- 2014-10-21 IL IL295045A patent/IL295045B2/en unknown
- 2014-10-21 KR KR1020227025504A patent/KR102602502B1/ko active Active
-
2015
- 2015-06-29 US US14/753,882 patent/US9249227B2/en active Active
-
2016
- 2016-04-13 IL IL245089A patent/IL245089B/en active IP Right Grant
- 2016-04-19 ZA ZA201602686A patent/ZA201602686B/en unknown
- 2016-04-19 MX MX2020009260A patent/MX2020009260A/es unknown
-
2017
- 2017-03-21 US US15/465,509 patent/US10385136B2/en active Active
-
2018
- 2018-12-26 JP JP2018241924A patent/JP6875363B2/ja active Active
-
2019
- 2019-07-02 US US16/460,593 patent/US10800853B2/en active Active
- 2019-10-28 AU AU2019257379A patent/AU2019257379B2/en active Active
-
2021
- 2021-04-06 AU AU2021202095A patent/AU2021202095B9/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202095B9 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
| Kumar et al. | Immunohistochemical localization of dopamine receptor subtypes (D1R–D5R) in Alzheimer's disease brain | |
| Faden et al. | Progressive inflammation‐mediated neurodegeneration after traumatic brain or spinal cord injury | |
| JP2014502141A5 (enExample) | ||
| JP2019059786A5 (enExample) | ||
| Fagoe et al. | Spinal cord injury and the neuron-intrinsic regeneration-associated gene program | |
| JP2020523326A5 (enExample) | ||
| AU2018225493B2 (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| JP2015517502A5 (enExample) | ||
| RU2018104962A (ru) | Снижение системного уровня регуляторных т-клеток или их активности для лечения заболеваний и трамв цнс | |
| JP2017504570A5 (enExample) | ||
| JP2018505651A5 (enExample) | ||
| EA202091650A1 (ru) | Неправильно свернутые tdp-43-связывающие молекулы | |
| JP2015520608A5 (enExample) | ||
| RU2017121836A (ru) | Нейродегенеративные расстройства | |
| JP2014502276A5 (enExample) | ||
| Kubo et al. | Repulsive guidance molecule-a and demyelination: implications for multiple sclerosis | |
| JP2022500360A (ja) | 神経変性疾患を治療する方法 | |
| JP2009519025A5 (enExample) | ||
| Villegas | Alzheimer's disease: New therapeutic strategies | |
| Cahill | Neuromyelitis optica spectrum disorders | |
| NZ736553A (en) | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders | |
| Kubo et al. | Crosstalk between the immune and central nervous system with special reference to drug development | |
| Guzik-Kornacka et al. | Blocking the Nogo-A Signaling Pathway to Promote Regeneration and Plasticity After Spinal Cord Injury and Stroke | |
| Lu et al. | Brain atrophy in autoimmune encephalitis: epidemiology, pathophysiology, clinical manifestations, treatment, and prognosis—an update |